| 注册
首页|期刊导航|中华医学杂志(英文版)|Clinical evaluation of valsartan and metoprolol tartrate in treatment of diabetic nephropathy with positive β1-adrenergic and anti-angiotensin Ⅱ type 1 receptor antibody

Clinical evaluation of valsartan and metoprolol tartrate in treatment of diabetic nephropathy with positive β1-adrenergic and anti-angiotensin Ⅱ type 1 receptor antibody

ZHAO Lin-shuang BAI Wei-wei XIANG Guang-da YUE Ling SUN Hui-ling

中华医学杂志(英文版)2012,Vol.125Issue(19):3543-3547,5.
中华医学杂志(英文版)2012,Vol.125Issue(19):3543-3547,5.DOI:10.3760/cma.j.issn.0366-6999.2012.19.033

Clinical evaluation of valsartan and metoprolol tartrate in treatment of diabetic nephropathy with positive β1-adrenergic and anti-angiotensin Ⅱ type 1 receptor antibody

Clinical evaluation of valsartan and metoprolol tartrate in treatment of diabetic nephropathy with positive β1-adrenergic and anti-angiotensin Ⅱ type 1 receptor antibody

ZHAO Lin-shuang 1BAI Wei-wei 1XIANG Guang-da 1YUE Ling 1SUN Hui-ling1

作者信息

  • 1. Department of Endocrinology, Wuhan General Hospital of People's Liberation Army Guangzhou Military Area Command,Wuhan, Hubei 430070, China
  • 折叠

摘要

Abstract

Background Studies have confirmed that angiotensin Ⅱ receptor blocker (ARB) and angiotensin converting enzyme inhibitors (ACEI) in the treatment of diabetic nephropathy (DN) has special advantages.We observed the effects of valsartan and metoprolol tartrate hydrchloride in treatment of DN patients with positive β1-adrenergic and anti-angiotensin Ⅱ type 1 (AT1) receptor antibody.Methods The epitopes of the second extracellular loop of β1 receptor (197-222) and AT1 receptor (165-191),were synthesized and used respectively to screen serum autoantibodies from patients with DN (n=371,group A),diabetes mellitus (DM) without renal failure (n=107,group B) and healthy blood donors (n=47,control,group C) by enzyme-linked immunosorbent assay (ELISA).Metoprolol tartrate 25-50 mg,three times per day,valsartan 160 mg,once a day,aspirin 100 mg,once a day,and nitrendipine 10-20 mg,three times per day,were given to DN patients with positive or negative autoantibodies.The cystatin C level and 24-hour urinary protein were measured before and after treatment.Results In DN patients,the positive rate of the autoantibodies against β1 receptors and AT1 receptor was 47.7% and 51.5%,respectively,which were significantly higher than those in DM patients and healthy controls (all P <0.01).Patients with anormalous cystatin C had higher positive rates of the autoantibodies than patients with normal cystatin C.Valsartan and metoprolol tartrate reduced proteinuria significantly (P <0.01) in DN patients with positive autoantibodies.Conclusions The findings suggest that these autoantibodies against β1 and AT1-receptor may play important roles in the pathogenesis of DN.Valsartan and metoprolol tartrate are effective and safe in the treatment of DN.Chin Med J 2012; 125(19):3543-3547

关键词

diabetic nephropathy/ β1-adrenergic receptor/ anti-angiotensin Ⅱ type 1 receptor/ valsartan/metoprolol tartrate

Key words

diabetic nephropathy/ β1-adrenergic receptor/ anti-angiotensin Ⅱ type 1 receptor/ valsartan/metoprolol tartrate

引用本文复制引用

ZHAO Lin-shuang,BAI Wei-wei,XIANG Guang-da,YUE Ling,SUN Hui-ling..Clinical evaluation of valsartan and metoprolol tartrate in treatment of diabetic nephropathy with positive β1-adrenergic and anti-angiotensin Ⅱ type 1 receptor antibody[J].中华医学杂志(英文版),2012,125(19):3543-3547,5.

基金项目

This study was supported by a grant from the Natural Science Foundation of Hubei Province (No.2002AB116). (No.2002AB116)

中华医学杂志(英文版)

OACSCDCSTPCDMEDLINESCI

0366-6999

访问量0
|
下载量0
段落导航相关论文